Overview

Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine wether RAD001 can inhibit growth of tumour cells and/or stop the formation and activity of bone degrading osteoclasts.
Phase:
Phase 2
Details
Lead Sponsor:
German Breast Group
Collaborator:
Novartis
Treatments:
Everolimus
Sirolimus